Enzon’s PEG-glucocerebrosidase
Executive Summary
IND filed for the treatment of Gaucher's disease. The company has been working with the National Institute of Mental Health, which developed glucocerebrosidase, under a Cooperative Research & Development Agreement signed in November 1991. The company's version of the recombinant compound is modified with Enzon's PEG- nology sustained-release technology, which it believes will allow smaller doses to be given at less frequent intervals than Genzyme's Cersdass. Enzon has completed a facility to supply the product for clinical trials.